Cancer du rein : traitements anti-angiogéniques et gestion des complications. À propos d'un cas

25 mars 2010

Auteurs : J.-P. Fendler, B. Malavaud, P. Gimel, B. Duclos, C. Chevreau, G. Pignot
Référence : Prog Urol, 2010, 20, S27, suppl. S1




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Gatenby R.A., Gillies R.J. A microenvironmental model of carcinogenesis Nat Rev Cancer 2008 ;  8 : 56-61 [cross-ref]
Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007 ;  6 : 273-286 [cross-ref]
Malavaud B., Tack I., Jonca F., Praddaude F., Moro F., Ader J.L., Plouët J. Activation of Flk-1/KDR mediates angiogenesis but not hypotension Cardiovasc Res 1997 ;  36 : 276-281 [cross-ref]
Isner J.M., Pieczek A., Schainfeld R., Blair R., Haley L., Asahara T., et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb Lancet 1996 ;  348 : 370-374 [cross-ref]
Rapp U.R., Goldsborough M.D., Mark G.E., Bonner T.I., Groffen J., Reynolds F.H., Stephenson J.R. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus Proc Natl Acad Sci U S A 1983 ;  80 : 4218-4222 [cross-ref]
Pritchard C.A., Bolin L., Slattery R., Murray R., McMahon M. Postnatal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene Curr Biol 1996 ;  6 : 614-617 [cross-ref]
Yeung K., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP Nature 1999 ;  401 : 173-177
Mc Henry K.T., Montesano R., Zhu S., Beshir A.B., Tang H.H., Yeung K.C., Fenteany G. Raf kinase inhibitor protein positively regulates cell-substratum adhesion while negatively regulating cell-cell adhesion J Cell Biochem 2008 ;  103 : 972-985 [cross-ref]
Hurwitz H.I., Dowlati A., Saini S., Savage S., Suttle A.B., Gibson D.M., et al. Phase I trial of pazopanib in patients with advanced cancer Clin Cancer Res 2009 ;  15 : 4220-4227 [cross-ref]
Sanders K.M., Ordög T., Ward S.M. Physiology and pathophysiology of the interstitial cells of Cajal: from bench to bedside. IV. Genetic and animal models of GI motility disorders caused by loss of interstitial cells of Cajal Am J Physiol Gastrointest Liver Physiol 2002 ;  282 : G747-G756
Sanders K.M., Ward S.M. Interstitial cells of Cajal: a new perspective on smooth muscle function J Physiol 2006 ;  576 : 721-726 [cross-ref]
Dematteo R.P., Ballman K.V., Antonescu C.R., Maki R.G., Pisters P.W., Demetri G.D., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 2009 ;  373 : 1097-1104 [cross-ref]
Vandeput F., Perpete S., Coulonval K., Lamy F., Dumont J.E. Role of the different mitogen-activated protein kinase subfamilies in the stimulation of dog and human thyroid epithelial cell proliferation by cyclic adenosine 5’-monophosphate and growth factors Endocrinology 2003 ;  144 : 1341-1349 [cross-ref]
Stuart N.S., Woodroffe C.M., Grundy R., Cullen M.H. Long-term toxicity of chemotherapy for testicular cancer--the cost of cure Br J Cancer 1990 ;  61 : 479-484 [cross-ref]
Franzke A., Peest D., Probst-Kepper M., Buer J., Kirchner G.I., Brabant G., et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer J Clin Oncol 1999 ;  17 : 529-533
Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafénib in advanced clear-cell renal-cell carcinoma N Engl J Med 2007 ;  356 : 125-134 [cross-ref]
Porta C., Szczylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma Cancer Treat Rev 2009 ;  35 : 297-307 [cross-ref]
Levy B.I. Microvascular plasticity and experimental heart failure Hypertension 2006 ;  47 : 827-829 [cross-ref]
Eisen T., Oudard S., Szczylik C., Gravis G., Heinzer H., Middleton R., et al. Sorafénib for older patients with renal cell carcinoma : subset analysis from a randomized trial J Natl Cancer Inst 2008 ;  100 : 1454-1463 [cross-ref]
Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma New Engl J Med 2007 ;  356 : 115-124 [cross-ref]
Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma New Engl J Med 2007 ;  356 : 2271-2281 [cross-ref]
Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 2007 ;  370 : 2103-2111 [cross-ref]
Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 2008 ;  372 : 449-456 [cross-ref]
Bellmunt J., Négrier S., Escudier B., Awada A., Aapro M.SIOG Taskforce The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce Crit Rev Oncol Hematol 2009 ;  69 : 64-72 [cross-ref]
Schmidinger M., Zielinski C.C., Vogl U.M., Bojic A., Bojic M., Schukro C., et al. Cardiac toxicity of sunitinib and sorafénib in patients with metastatic renal cell carcinoma J Clin Oncol 2008 ;  26 : 5204-5212 [cross-ref]
Wörns M.A., Weinmann A., Pfingst K., Schulte-Sasse C., Messow C.M., Schulze-Bergkamen H., et al. Safety and efficacy of sorafénib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis J Clin Gastroenterol 2009 ;  43 : 489-495






© 2010 
Elsevier Masson SAS. Tous droits réservés.